Advanced search
Publication Cover
Breast Cancer: Targets and Therapy Volume 13, 2021 - Issue
Submit an article Journal homepage
177
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation

Jamie Smith1 Rocky Mountain Cancer Centers Littleton, Denver, CO, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8830-9664
ORCID Icon,
Charles Leonard1 Rocky Mountain Cancer Centers Littleton, Denver, CO, USAORCID Iconhttps://orcid.org/0000-0003-2250-9329
ORCID Icon,
Dennis L Carter2 Rocky Mountain Cancer Centers Aurora, Denver, Co, USA
&
Shannon Tole1 Rocky Mountain Cancer Centers Littleton, Denver, CO, USA
Pages 513-517 | Published online: 29 Aug 2021

References

  • SmithBD, ArthurDW, BuchholzTA, et al. Accelerated Partial Breast Irradiation Consensus Statement for the American Society for Radiation Oncology (ASTRO). Int J Radiation Oncology Biol Phys. 2009;74:987–1001. doi:10.1016/j.ijrobp.2009.02.031
  • CorreaC, HarrisEE, LeonardiMC, et al. Accelerated Partial Breast Irradiation: executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017;7:73–79. doi:10.1016/j.prro.2016.09.00727866865
  • PolgárC, LimbergenEV, PötterR, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiotherapy Oncol. 2010;94(3):264
  • LeiRY, LeonardCE, HowellKT, et al. Four-year clinical update from a prospective trial of accelerated partial breast intensity-modulated radiotherapy (APBIMRT). Breast Cancer Res Treat. 2013;140(1):119–133. doi:10.1007/s10549-013-2623-x23824363
  • LeonardC, CarterD, KercherJ, et al. Prospective trial of accelerated partial breast intensity-modulated radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 2007;67(5):1291–1298. doi:10.1016/j.ijrobp.2006.11.016
  • ChagparA, MiddletonLP, SahinAA, et al. Clinical outcome of patients with lymph node‐negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. Int J Am Cancer Soc. 2005;103(8):1581–1586.
  • TalletA, LambaudieE, CohenM, et al. Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy. World J Clin Oncol. 2016;7(2):243. doi:10.5306/wjco.v7.i2.24327081647
  • ChagparA, MiddletonLP, SahinAA, et al. Clinical outcome of patients with lymph node‐negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005;103(8):1581–1586. doi:10.1002/cncr.2093415747375
  • MillisRR, SpringallR, LeeAH, RyderK, RytinaER, FentimanIS. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer. 2002;86(3):396. doi:10.1038/sj.bjc.660007011875706
  • KaramI, LesperanceMF, BerrangT, SpeersC, TyldesleyS, TruongPT. pN0 (i+) breast cancer: treatment patterns, locoregional recurrence, and survival outcomes. Int J Radiation Oncol. 2013;87(4):731–737. doi:10.1016/j.ijrobp.2013.07.028
  • CoxCE, KilukJV, RikerAI, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg. 2008;206(2):261–268. doi:10.1016/j.jamcollsurg.2007.08.02418222378
  • HerbertGS, SohnVY, BrownTA. The impact of nodal isolated tumor cells on survival of breast cancer patients. Am j Surg. 2007;193(5):571–574. doi:10.1016/j.amjsurg.2007.01.00717434357
  • McGuckinMA, CummingsMC, WalshMD, HohnBG, BennettIC, WrightRG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer. 1996;73(1):88–95. doi:10.1038/bjc.1996.168554990
  • NasserIA, LeeAK, BosariS, SaganichR, HeatleyG, SilvermanML. Occult axillary lymph node metastases in “node-negative” breast carcinoma. Hum Pathol. 1993;24(9):950–957. doi:10.1016/0046-8177(93)90108-S7504652
  • PuglieseMS, BeattyJD, TickmanRJ, et al. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0 (i+) and pN1mi categories. Ann Surg Oncol. 2009;16(1):113–120. doi:10.1245/s10434-008-0121-x18949520
  • MillisRR, SpringallR, LeeAH, RyderK, RytinaER, FentimanIS. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer. 2002;86(3):396–401.11875706
  • ColpaertC, VermeulenP, JeurisW, et al. Early distant relapse in ‘node‐negative’breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol. 2001;193(4):442–449. doi:10.1002/path.82911276002
  • de MascarelI, MacGroganG, DebledM, BrousteV, MauriacL. Distinction between isolated tumor cells and micrometastases in breast cancer: is it reliable and useful?Cancer. 2008;112(8):1672–1678. doi:10.1002/cncr.2336818286534
  • TanLK, GiriD, HummerAJ, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol. 2008;26(11):1803–1809. doi:10.1200/JCO.2007.12.642518332473
  • QuerzoliP, PedrialiM, RinaldiR, et al. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res. 2006;12(22):6696–6701. doi:10.1158/1078-0432.CCR-06-056917121888

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.